ArticleAddiction science & clinical practice2026
Telemedicine and increased retention in medications for opioid use disorder treatment.
Article in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBuprenorphine is an effective treatment for Opioid Use Disorder (OUD), but many patients discontinue this medication within six-months of initiation and racial disparities in access and retention in buprenorphine treatment exist. Telemedicine is a potentially promising strategy to improve buprenorphine treatment retention.
objectiveTo determine if, compared to pre-pandemic in-person services, telemedicine visits were associated with increased retention in MOUD treatment at six-months and if there were differences by race.
methodsThis is a retrospective cohort study that evaluated medical records of individuals treated for OUD in-person (n = 247) and via telemedicine (n = 204) at a large academic medical center in the Southeastern United States from 2018 to 2021. The primary outcome was the percentage of patients retained in treatment at six-months, defined as having an outpatient visit associated with a buprenorphine prescription. Chi-squared tests were used to evaluate the percentage of patients retained in treatment at six-months, multivariable logistic regression identified correlates of retention, and Kaplan-Meier survival analyses evaluated time in treatment.
results35.3% of the cohort (n = 411; M
conclusionThis study suggests that retention in treatment may be higher with telemedicine-based buprenorphine treatment compared to in-person care. Non-White patients appeared to experience an even greater benefit, though further research is needed to confirm this finding. As policymakers are determining telehealth prescribing laws, these findings further support the use of telemedicine to improve retention in effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.